Biogen Inc. (BIIB)

Common-Size Income Statement

Difficulty: Beginner

Annual Data

Quarterly Data

Biogen Inc., Common-Size Consolidated Income Statement

12 months ended	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013
Product, net
Revenues from anti-CD20 therapeutic programs
Other
Revenues	%	%	%	%	%
Cost of sales, excluding amortization of acquired intangible assets
Gross profit	%	%	%	%	%
Research and development
Selling, general and administrative
Amortization of acquired intangible assets
Acquired in-process research and development
Collaboration profit sharing
Gain (loss) on fair value remeasurement of contingent consideration
Restructuring charges
TECFIDERA litigation settlement charges
Gain on sale of rights
Income from operations	%	%	%	%	%
Interest income
Interest expense
Impairments on investments
Gain (loss) on investments, net
Foreign exchange gains (losses), net
Other, net
Other income (expense), net	%	%	%	%	%
Income before income tax expense and equity in loss of investee, net of tax	%	%	%	%	%
Income tax expense
Equity in loss of investee, net of tax
Net income	%	%	%	%	%
Net (income) loss attributable to noncontrolling interests, net of tax
Net income attributable to Biogen Inc.	%	%	%	%	%

	Biogen Inc.	Other companies (not purchased previously)
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality

	All companies
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality